Ozone therapy immunomodulatory effect in the selective immunoglobulin A deficiency.

Abstract

The aim of this work is to study the ozone therapy effect in the selective immunoglobulin A deficiency. Taking into account that ozone is able to stimulate several biological systems, to modulate cytokines levels and to enhance immunoglobulin production, a phase II, controlled and randomized, clinical trial was performed. Forty patients were divided at random into 2 groups of 20 patients each: Ozone – received 42 sessions by rectal insufflations during three months, using scaling doses. Control – received subcutaneous Hebertrans during three months. Patients were evaluated at the beginning and one and six months later. The IgA improved, with significant difference (p=0.04) between both groups. The blood levels of IgG were increased significantly (p=0.03) in the group treated with ozone compared to the control group. Leukocyte activity improved significantly (p=0.04) one month later, achieving 97 % of normal values. The clinical evolution was satisfactory in 87 and 80 % of the children that received ozone and Hebertrans, respectively without side effects reported.

Ozone Therapy for Breast Cancer: An Integrative Literature Review

“… 3 , 28 The effects of ozone on macrophages, T cells, B cells, NK cells, and dendritic cells can be used in the treatment of infectious diseases, autoimmune disorders, and cancer immunotherapy. 1 In clinical use, ozone therapy not only increases leukocyte activity and the immunoglobulin G (IgG) level in patients with selective immunoglobulin A deficiency, 29 but ozone has also been shown to increase the production of both IL-8 and tumor necrosis factor alpha (TNF-α) in a human monocytic cell line (THP-1 cell) model. 1 , 30 , 31 Owing to its immunomodulatory and anti-inflammatory effects, ozone affects the tumor microenvironment (TME), which plays a critical role in cancer initiation, progression, and response to therapy.…”

Theoretical Basements for a Clinical Trial on COVID-19 Patients with Systemic Ozone Therapy

“…Years later, another in vitro studies showed that 40mcg/mL produced optimal modulation on NFKβ and pro inflammatory cytokines without any side effect [75,76]. Primary IgA deficiency patients found more improvement with systemic ozone that with Transfer Factor 1 [77]. In secondary immunodeficiency pediatric patients treated with systemic ozone also improved clinically with a decrease in the infection rate and without side effects [78].…”

Could ozone become a complementary therapeutic approach to improve metabolic and endocrine response of ALS patients?

“…In this context, clinical trials evidenced the effectiveness of O 3 therapy in the treatment of multiple sclerosis 2,3,5 , due to its potential to induce controlled oxidative stress 6 , through mechanism of action involving its interaction with the nuclear factor erythroid-derived 2-like 2 (Nrf2) 3 , a key regulator of inducible antioxidant responses 7 . Additionally, clinical data indicated the immunomodulatory effect of O 3 therapy 8 , and animal work demonstrated the effectiveness of this gas to activate the hypothalamic-pituitary-adrenal axis, which has the potential to alter the composition of the gut microbiota and increase gastrointestinal permeability 9,10 , suggesting the potential role of O 3 to induce controlled metabolic effects.…”